Concert Pharmaceuticals Inc. (CNCE) announced Friday morning that its Post Grant Review petition challenging the validity of U.S. Patent No. 9,662,335 assigned to Incyte Pharmaceuticals has been denied by the U.S. Patent and Trademark Office.
The company also announced this morning that it has been granted Fast Track designation by the FDA for CTP-543.
Concert Pharmaceuticals gapped open sharply lower this morning and has continued to decline in early trade. Shares are now down 7.11 at $20.57 on above average volume. The stock has dropped to nearly a 2-month low.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.